Cancer name T Lymphoma
Cancer Type TL
Immunotherapy type Adoptive Cell Therapy
Treatment ACT CD8+ T-cells
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature IDO
Official Symbol IDO1
Mode of action PROT_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description The levels of cleaved caspase-3 in tumors were most increased, by contrast, IDOs were severely decreased on day 3 post ACT in two combination groups assayed with Western blot.
PMID 26683520
Title Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice